09 Nov Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
Anaheim Bio Series A: Leiden-based biotech raises €40M to advance ANA-1, a small molecule for CPPD, into the clinic in 2027....
Anaheim Bio Series A: Leiden-based biotech raises €40M to advance ANA-1, a small molecule for CPPD, into the clinic in 2027....
Unnatural Products Series B financing secures $45M after a Novartis pact to advance macrocycle drugs toward the clinic....